Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment In an interview with Pharmaceutical Executive, Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from ...

Real-world evidence (RWE) is no longer optional—it's expected. This episode dives into how payers assess RWE alongside clinical trial data, especially in competitive therapeutic areas. The panel ...